Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Rhea-AI Summary

Incannex Healthcare (Nasdaq: IXHL) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid of $1.00 or greater for eleven consecutive business days from February 27 through March 13, 2026. Nasdaq has confirmed the company satisfied continued listing requirements and the matter is closed.

The company reported approximately $75 million in cash, no debt, and cited ongoing clinical development of IHL-42X for obstructive sleep apnea (statistically significant Phase 2) and PSX-001 for generalized anxiety disorder (positive outcomes).

Positive

• Nasdaq compliance restored after 11 consecutive business days at $1.00+ closing bid
• Balance sheet strength: approximately $75 million cash and no debt
• Clinical progress: IHL-42X showed statistically significant Phase 2 results

Negative

• Prior listing deficiency created a technical overhang on the stock before remediation

Key Figures

Minimum bid price: $1.00 per share Compliance streak: 11 business days Cash balance: Approximately $75 million +1 more

4 metrics

Minimum bid price $1.00 per share Nasdaq Listing Rule 5550(a)(2) compliance threshold

Compliance streak 11 business days Closing bid at or above $1.00 from Feb 27–Mar 13, 2026

Cash balance Approximately $75 million Management statement on liquidity and no debt

Phase 2 status Phase 2 results IHL-42X demonstrated statistically significant Phase 2 outcomes

Market Reality Check

Price: $3.31 Vol: Volume 609,418 is at 0.83...

normal vol

$3.31 Last Close

Volume Volume 609,418 is at 0.83x its 20-day average of 737,381, suggesting no unusual trading response. normal

Technical Shares at 3.31 are trading below the 200-day MA of 11.62, despite regaining Nasdaq bid-price compliance.

Peers on Argus

IXHL gained 1.85% while closely related peers like SCYX, AYTU, CPIX, TLPH, and R...

IXHL gained 1.85% while closely related peers like SCYX, AYTU, CPIX, TLPH, and RMTI all showed positive moves, but none appeared in the momentum scanner, indicating a stock-specific reaction rather than a confirmed sector rotation.

Historical Context

5 past events · Latest: Mar 12 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Registered direct offering	Negative	-48.4%	Dilutive $10M registered direct offering with accompanying warrants.
Mar 12	Clinical pathway update	Positive	-48.4%	Enhanced development plan for IHL-42X after positive Phase 2 data and Fast Track.
Feb 25	Reverse stock split	Negative	-42.1%	1-for-30 reverse split to boost share price and support Nasdaq compliance.
Feb 18	Analyst coverage update	Positive	+8.3%	Coverage highlighting strong Phase 2 IHL-42X results and $68.9M cash balance.
Jan 29	Advisory board additions	Neutral	-0.6%	Three new Clinical Advisory Board members to support PSX-001 development.

Pattern Detected

Recent history shows heavy selling on financing and structural actions (reverse split, registered direct), with one notable divergence where positive clinical news coincided with a sharp decline, suggesting sensitivity to dilution and capital-structure changes.

Recent Company History

Over the last few months, IXHL has combined clinical progress with significant capital-structure moves. A 1-for-30 reverse split on Feb 26 and a $10M registered direct offering on Mar 12 both preceded steep declines. At the same time, IHL-42X delivered statistically significant Phase 2 outcomes and received FDA Fast Track, and coverage updates highlighted $68.9M in cash. Today’s bid-price compliance update links back to the reverse split strategy aimed at maintaining Nasdaq listing.

Market Pulse Summary

This announcement confirms that IXHL met Nasdaq’s minimum bid price rule after maintaining at least ...

Analysis

This announcement confirms that IXHL met Nasdaq’s minimum bid price rule after maintaining at least $1.00 per share for 11 consecutive business days, closing out a listing overhang that followed the 1-for-30 reverse split. Management also highlights approximately $75 million in cash and no debt alongside statistically significant Phase 2 results for IHL-42X and positive outcomes for PSX-001. Investors may monitor future clinical milestones and any additional financing steps in light of recent offerings and ongoing net losses.

Key Terms

minimum bid price requirement, phase 2, obstructive sleep apnea, generalized anxiety disorder

4 terms

minimum bid price requirement regulatory

"regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

phase 2 medical

"IHL-42X for obstructive sleep apnea, which has demonstrated statistically significant Phase 2 results"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

obstructive sleep apnea medical

"continued development of IHL-42X for obstructive sleep apnea, which has demonstrated statistically significant Phase 2 results"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

generalized anxiety disorder medical

"PSX-001 for the treatment of generalized anxiety disorder, which has also generated positive clinical outcomes"

Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.

AI-generated analysis. Not financial advice.

MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced that it has regained compliance with the Nasdaq minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

The Company received written confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement after its common stock maintained a closing bid price of $1.00 per share or greater for eleven consecutive business days, from February 27 through March 13, 2026.

As a result, the Company has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now considered closed.

“We are pleased to have regained compliance with Nasdaq’s minimum bid price requirement, which reinforces our continued listing on the Nasdaq Capital Market and removes a technical overhang that has weighed on the Company,” said Joel Latham, President and Chief Executive Officer of Incannex Healthcare. “With approximately $75 million in cash, no debt, and a disciplined development strategy, we believe Incannex is exceptionally well positioned to advance our pipeline of differentiated clinical programs. This includes the continued development of IHL-42X for obstructive sleep apnea, which has demonstrated statistically significant Phase 2 results, as well as PSX-001 for the treatment of generalized anxiety disorder, which has also generated positive clinical outcomes. As we progress these programs through upcoming milestones, our focus remains on executing our clinical strategy, further de-risking our assets, and unlocking the long-term value of our pipeline for patients and shareholders.”

About Incannex Healthcare Inc. 

Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at www.incannex.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to preliminary financial information; any implication the Company will continue to meet the requirements for continued listing on the Nasdaq Capital Market; management’s expectations and beliefs regarding the development pathway for IHL-42X and Company’s positioning to execute on its strategies and create value for shareholders. When or if used in this communication, the words "may," "could," “considered,” "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," “positioned,” "predict" and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: that Incannex may fail to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated; the success or failure of Incannex’s development efforts, including Incannex’s ability to progress its drug candidates through clinical trials on the timelines expected and to obtain necessary regulatory approvals for commercialization of its drug candidates; and other risks described in the section entitled "Risk Factors" described in the prospectus supplement and in the Company's annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com  
media@incannex.com.au 

FAQ

How did Incannex (IXHL) regain Nasdaq compliance on March 17, 2026?

Incannex regained compliance by maintaining a closing bid of $1.00 or greater for eleven consecutive business days. According to the company, this period ran from February 27 through March 13, 2026 and satisfied Nasdaq Listing Rule 5550(a)(2).

What does Nasdaq confirmation mean for Incannex (IXHL) shareholders?

Nasdaq confirmation means the company retains its listing and the prior technical overhang is removed. According to the company, the listing matter is now considered closed, reducing a near-term regulatory risk for shareholders.

What is Incannex's reported cash position and debt status as of March 17, 2026?

Incannex reported approximately $75 million in cash and no debt. According to the company, this cash position supports its disciplined development strategy and upcoming clinical milestones.

What clinical programs did Incannex highlight in the March 17, 2026 announcement?

Incannex highlighted IHL-42X for obstructive sleep apnea with statistically significant Phase 2 results and PSX-001 for generalized anxiety disorder with positive outcomes. According to the company, both programs will progress toward upcoming milestones.

Will regaining Nasdaq compliance change Incannex's near-term listing status (IXHL)?

Yes; regaining compliance preserves the company's continued listing on the Nasdaq Capital Market. According to the company, Nasdaq has provided written confirmation and the compliance matter is closed.